| __timestamp | AstraZeneca PLC | Catalyst Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5579000000 | 10117774 |
| Thursday, January 1, 2015 | 5997000000 | 11801342 |
| Friday, January 1, 2016 | 5890000000 | 11369941 |
| Sunday, January 1, 2017 | 5757000000 | 11375237 |
| Monday, January 1, 2018 | 5932000000 | 19919204 |
| Tuesday, January 1, 2019 | 5958000000 | 18842752 |
| Wednesday, January 1, 2020 | 5991000000 | 16496715 |
| Friday, January 1, 2021 | 9736000000 | 16936000 |
| Saturday, January 1, 2022 | 9762000000 | 19789000 |
| Sunday, January 1, 2023 | 10935000000 | 93150000 |
| Monday, January 1, 2024 | 13583000000 |
Unveiling the hidden dimensions of data
In the ever-evolving landscape of pharmaceutical research, AstraZeneca PLC and Catalyst Pharmaceuticals, Inc. stand as intriguing contrasts. Over the past decade, AstraZeneca has consistently invested heavily in research and development (R&D), with expenses peaking at approximately $10.9 billion in 2023, marking a 96% increase from 2014. This commitment underscores AstraZeneca's role as a global leader in pharmaceutical innovation.
Conversely, Catalyst Pharmaceuticals, a smaller player, has shown a more modest yet significant growth in R&D spending. From 2014 to 2023, their expenses surged by over 800%, reaching nearly $93 million. This growth reflects Catalyst's strategic focus on niche markets and specialized treatments.
The data highlights the diverse strategies of these companies: AstraZeneca's broad-spectrum approach versus Catalyst's targeted innovation. As the pharmaceutical industry continues to evolve, these differing strategies offer valuable insights into the future of drug development.
Research and Development Expenses Breakdown: AstraZeneca PLC vs Zoetis Inc.
AstraZeneca PLC vs Verona Pharma plc: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for AstraZeneca PLC and Rhythm Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for AstraZeneca PLC and Iovance Biotherapeutics, Inc.
Research and Development Investment: AstraZeneca PLC vs Celldex Therapeutics, Inc.
Comparing Innovation Spending: Gilead Sciences, Inc. and Catalyst Pharmaceuticals, Inc.
R&D Insights: How Bio-Techne Corporation and Catalyst Pharmaceuticals, Inc. Allocate Funds
Research and Development Investment: Pharming Group N.V. vs Catalyst Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Grifols, S.A. vs Catalyst Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Corcept Therapeutics Incorporated and Catalyst Pharmaceuticals, Inc.
Comparing Innovation Spending: CymaBay Therapeutics, Inc. and Catalyst Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Catalyst Pharmaceuticals, Inc. and Evotec SE